News

Date	Title and Summary	Additional Formats
Toggle SummaryAug 11, 2014	Study Indicates Cost Effectiveness of Intersect ENT’s PROPEL Implant for Chronic Sinusitis Study Author Assesses Significant Productivity Loss from Chronic Sinusitis	Study Indicates Cost Effectiveness of Intersect ENT’s PROPEL Implant for Chronic Sinusitis Study Author Assesses Significant Productivity Loss from Chronic Sinusitis 49.4 KB
Toggle SummarySep 03, 2014	Intersect ENT Reports Second Quarter 2014 Results Second Quarter Revenue Increased 118% Year-Over-Year to $8.6 Million	View HTML Intersect ENT Reports Second Quarter 2014 Results 21.2 KB
Toggle SummarySep 17, 2014	Intersect ENT Enrolls First Patient in Clinical Study to Expand Access to PROPEL Treatment to Broader Patient Population	Intersect ENT Enrolls First Patient in Clinical Study to Expand Access to PROPEL Treatment to Broader Patient Population 84.7 KB
Toggle SummarySep 22, 2014	Intersect ENT Announces Positive Data from Clinical Trial of New In-Office Implant for Recurrent Chronic Sinusitis	Intersect ENT Announces Positive Data from Clinical Trial of New In-Office Implant for Recurrent Chronic Sinusitis 178.8 KB
Toggle SummaryOct 01, 2014	Intersect ENT Added to Russell 2000 Index MENLO PARK, Calif., Oct. 1, 2014 (GLOBE NEWSWIRE) -- Intersect ENT (Nasdaq:XENT), a company dedicated to improving the quality of life for patients with ear, nose and throat conditions, today announced that the Company has been added to the Russell 2000 ® index, effective as of the close of	View HTML Intersect ENT Added to Russell 2000 Index 9.7 KB
Toggle SummaryOct 08, 2014	Intersect ENT Announces Positive Data from Clinical Trial of New In-Office Implant for Recurrent Chronic Sinusitis	Intersect ENT Announces Positive Data from Clinical Trial of New In-Office Implant for Recurrent Chronic Sinusitis 31.6 KB
Toggle SummaryOct 24, 2014	Intersect ENT Named “Fastest Growing” in San Francisco and Silicon Valley	Intersect ENT Named “Fastest Growing” in San Francisco and Silicon Valley 23.4 KB
Toggle SummaryNov 05, 2014	Intersect ENT Reports Third Quarter 2014 Results Third Quarter Revenue Increased 113% Year-Over-Year to $9.1 Million	View HTML Intersect ENT Reports Third Quarter 2014 Results 21.3 KB
Toggle SummaryDec 10, 2014	Intersect ENT Announces Changes to Board of Directors MENLO PARK, Calif., Dec. 10, 2014 (GLOBE NEWSWIRE) -- Intersect ENT, Inc. (Nasdaq:XENT), a company dedicated to improving the quality of life for patients with ear, nose and throat conditions, today announced the resignations of Rick Anderson, PTV Healthcare Capital, and Mark Fletcher, Medtronic,	View HTML Intersect ENT Announces Changes to Board of Directors 9.9 KB
Toggle SummaryDec 29, 2014	Intersect ENT Announces Enrollment of First Patient In Phase III Study of In-Office Treatment for Recurrent Chronic Sinusitis	Intersect ENT Announces Enrollment of First Patient In Phase III Study of In-Office Treatment for Recurrent Chronic Sinusitis 30.5 KB

Investor Relations

News